EICHORPublic-registry site landscape for NCT06940154, “Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)”, a COPD Acute Exacerbation study sponsored by Connect Biopharm LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06940154 (registry record) |
| Study title | Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) |
| Official title | A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Chronic Obstructive Pulmonary Disease and Type 2 Inflammation |
| Sponsor | Connect Biopharm LLC |
| Condition(s) | COPD Acute Exacerbation |
| Phase | PHASE2 |
| Listed sites | 53 |
| Site countries | United States, Argentina, Australia, Georgia, Serbia, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT06940154.
Eichor generates a preliminary site-risk snapshot for NCT06940154 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
